Search

A fadiga relacionada ao câncer é um dos sintomas que mais impacta a qualidade de vida de pacientes em tratamento para o câncer de mama. A prática de Yoga vem sendo utilizada como intervenção não farmacológica para atenuar os sintomas durante o tratamento para o câncer de mama. No entanto, são necessários mais estudos, a fim de elucidar e preencher possíveis lacunas acerca dos efeitos da prática de Yoga nesta população. Este artigo descreve o protocolo de um ensaio clínico randomizado que tem como objetivo analisar os efeitos de um programa de Yoga, em comparação com um grupo controle, sobre desfechos físicos e psicológicos de pacientes diagnosticadas com câncer de mama em tratamento pelo Sistema Único de Saúde (SUS) na cidade de Pelotas-Rio Grande do Sul. Trinta mulheres serão randomizadas em grupo Yoga ou controle. As participantes do grupo Yoga serão submetidas a um programa de Yoga, associado com educação em saúde, duas vezes por semana durante oito semanas, com duração de 60 minutos cada sessão. O grupo controle participará apenas de encontros de educação em saúde, uma vez por semana, também durante oito semanas e com encontros de 60 minutos. Serão realizadas avaliações da fadiga relacionada ao câncer, qualidade de vida, dor, capacidade funcional e nível de atividade física no lazer pré e pós intervenção. Para analisar os dados será utilizado o teste Generalized Estimating Equations e post-hoc de Bonferroni (α = 0,05). O protocolo do estudo está registrado no Registro Brasileiro de Ensaios Clínicos sob o número RBR-6vk2vjr.

Copyright of Arquivos de Ciências da Saúde da UNIPAR is the property of Associacao Paranaense de Ensino e Cultura and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The objective of this study was to understand the perception of women with breast cancer about treatments. This is a qualitative, descriptive, cross-sectional study, involving 40 women undergoing chemotherapy for the treatment of breast cancer in a hospital specialized in oncology. The instrument used for data collection was a semi-structured interview. Data was analyzed using Bardin's Content Analysis and categorized according to the Health Belief Model. Four categories emerged: "Perceived susceptibility: cancer and COVID-19", "Perception of severity in view of treatments impact", "Challenges and barriers in treatments" and "Perceived benefits in cancer treatment". It is concluded that there are different factors that resonate in women's perception of treatments and that generate repercussions in the way of facing them. Knowledge of these factors by healthcare professionals can help in providing better assistance to women in facing the disease. [ABSTRACT FROM AUTHOR]

Introdução: O câncer de mama (CM) é a neoplasia maligna com maior incidência e mortalidade entre as mulheres em todo o mundo. O estado nutricional (EN) antes e após o tratamento quimioterápico pode ser decisivo para o prognóstico e sobrevida do paciente com CM. Objetivo: Portanto, este estudo teve como objetivo revisar sistematicamente o EN antes e após a quimioterapia em mulheres com CM. Métodos: Uma extensa pesquisa foi realizada nas bases de dados Pubmed, Web of Science e Scopus. A busca limitou-se a manuscritos publicados até 2020 utilizando o método booleano com as seguintes combinações de descritores: “câncer de mama” E “estado nutricional” E “quimioterapia”. Resultados: Um total de 12 artigos foram incluídos nesta revisão. Em relação ao EN pré-quimioterapia, dois estudos foram com pacientes com diagnóstico de eutrofia e 10 estudos foram com pacientes com sobrepeso. Em relação ao EN pós-tratamento, nove estudos foram com pacientes com sobrepeso, dois com pacientes eutróficos e um com pacientes em risco nutricional. Conclusão: Vários estudos confirmam a associação entre CM e sobrepeso/obesidade com aumento da prevalência da doença, pior prognóstico e redução da sobrevida após o término do tratamento. Os dados atuais suportam a necessidade de intervenções no estilo de vida dos pacientes. Novos estudos sobre a associação entre intervenções no CM devem ser realizados a fim de formar um corpo maior de evidências.

Introduction: Breast cancer continues to be one of the main priorities in global health and public health, given that it remains the most frequent and deadly malignant neoplasm in women worldwide. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare type of non-Hodgkin's lymphoma, whose pathogenesis and pathophysiology are not well known, but which is seen with increasing frequency due to the increase in cosmetic procedures. To date, there are limitations in terms of knowledge about the clinical behavior of the disease, which can manifest itself in many forms, with a variable evolution time and uncertain surgical outcomes in the medium- and long-term. Based on the above, the aim of this review is to summarize evidence on the clinical considerations and surgical outcomes of breast implant-associated cancer to facilitate the identication and management of this condition. A bibliographic search was performed in the search engines and databases PubMed, ScienceDirect, Embase, EBSCO and MEDLINE. Within the clinical and surgical considerations, the type of implant used (textured), the time of the implant history, the severity of the manifestations, and the staging, must be taken into account in order to determine the opportunity for surgical intervention and neoadjuvant therapy, and to try to guarantee survival and avoid recurrence. Patients who undergo complete capsulectomy with radiotherapy have better outcomes. [ABSTRACT FROM AUTHOR]

Copyright of Scire Salutis is the property of CBPC - Companhia Brasileira de Producao Cientifica and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

A qualitative study to understand the spiritual/religious/social support network in the experience of breast cancer and the COVID-19 pandemic. The following theoretical and methodological frameworks were used, respectively: Symbolic Interactionism and Grounded Theory. The study participants were 13 social actresses, and data collection and analysis took place between August 2020 and June 2021. The central category was "Experiencing breast cancer in the context of the COVID-19 pandemic and the importance of the spiritual/religious/social support network to face this moment positively". This network contributed to the positive experience of the moment, with better adaptation to reality (breast cancer, social distancing, and the COVID-19 pandemic). [ABSTRACT FROM AUTHOR]

Antecedent and Objective: In Peru, the presentation of TZM-IV and TZM-SC is carried out. But there is no comparative cost data by route of administration. The objective of our study was to know the costs of patients with breast cancer, comparing the routes of administration in a regional cancer center in Peru., Material and Methods: In 2020, patients who were prescribed TZM treatment were prospectively recorded clinical, demographic and transport data, and medical costs were obtained from medical history and pharmacy records. With these data, the simulation was performed in 100 patients who received 18 cycles of the drug., Results: The main contributor to the cost of the difference was the cost of the drug itself, being S/. 4,711.11 (1,323.35 USD) and S/. 4,680.30 (1,314.69 USD) for TZM-IV and TZM-SC, respectively. The administration costs to treat 100 patients with complete cycles of TZM-IV and TZM-SC were S/. 334,488.53 (93,957.45 USD) and S/.207,455.33 (58,873.97 USD), respectively. Indirect costs indicate that patients lost in total, S/. 1,123.28 (315.53 USD) and S/. 1,148.60 (322.64 USD) in TZM-IV and TZMSC per patient, respectively., Conclusions: The use of TZM-SC is recommended, in the scenario of a lower cost of the drug and a shorter duration of administration time. Especially in a country with low funding, which only allows subsidizing the direct costs of cancer treatment., (Copyright © 2021 FECA. Publicado por Elsevier España, S.L.U. All rights reserved.)